VERV — Verve Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $462.65m
- -$61.63m
- $32.33m
- 46
- 20
- 51
- 33
Annual cashflow statement for Verve Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -45.7 | -120 | -157 | -200 | -199 |
| Depreciation | |||||
| Non-Cash Items | 6.47 | 43.8 | 23.9 | 27.4 | 36.5 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.64 | -2.91 | 8.38 | 17.7 | -2.26 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -35.3 | -77.9 | -122 | -150 | -158 |
| Capital Expenditures | -3.42 | -4.36 | -13.2 | -9.28 | -3.74 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -47.7 | -235 | -143 | 37 | 78.6 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -51.1 | -239 | -156 | 27.7 | 74.9 |
| Financing Cash Flow Items | — | -2.85 | -0.783 | -0.458 | -0.066 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 92.6 | 377 | 329 | 213 | 49.2 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.24 | 60.1 | 50.7 | 90.7 | -33.6 |